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Summary A sequential, quantitative loss of Peanut agglutinin (PNA) binding with progression of mouse
mammary cells from normal to preneoplastic to neoplastic phenotypes was observed. Normal mammary
epithelium, preneoplastic mammary lesions designated D2HAN (D2-type hyperplastic alveolar nodules) and a
series of nine spontaneous tumours (D2ST1, D2ST2, D2ST3, D2ST4, D2AI, D2F2, D2.OR, D2.1, EMT6RO8)
derived from mice bearing D2HAN were grown in culture and analysed by flow cytometry with respect to
PNA binding intensity to the cell surface. Primary cultures of normal mammary epithelium strongly bound
PNA. A stepwise decrease in PNA binding by preneoplastic D2HAN cells and subsequent tumours arising
from those hyperplastic lesions was observed. Three cloned tumour subpopulations derived from such tumours
exhibited dramatic differences in PNA binding ranging from high (D2.OR) to low (D2.1) to very low (D2AI
cells). Their growth rate in vitro was similar. However, an inverse correlation between PNA binding and
malignant characterstics, such as the incidence and latency of subcutaneous tumours and the efficiency of the
tumour cells to form lung colonies after i.v. injection, existed. Cells subsequently derived from tumours
resulting from injection of the D2.OR clone (high PNA binding, low tumorigenicity) were found to have
diminished PNA binding properties and to be more tumorigenic when reimplanted into syngeneic mice. The
difference in PNA binding (up to 50-fold) between normal mammary cells and other mouse mammary tumour
cells, i.e., unrelated to D2HAN lesions, was also seen. These include six sister subpopulations derived from a
single BALB/cfC3H mouse mammary tumour (lines: 67, 66c14, 168FARN, 4TO7, 68H, 64pT) as well as SPI
spontaneous CBA/J mouse mammary carcinoma. The difference was greatly reduced by neuraminidase
treatment suggesting a masking of PNA binding sites by sialic acid.
Separation of cell lysates by SDS-PAGE revealed a high molecuar weight PNA binding glycoprotein
(>250 kd) expressed by normal mammary epithelium and preneoplastic D2HAN cells, but not by tumour
cells regardless of neuraminidase treatment. A PNA reactive glycoprotein of approximately 90 kd was uniquely
expressed in normal mammary epithelial lysates, although neuraminidase treatment exposed a similar band in
a few tumour lines. Normal mammary epithelium, preneoplastic D2HAN cells, and the poorly tumorigenic
clone D2.OR expressed a PNA binding glycoprotein of approximately 150kd. This band appeared to be
specifically sialylated during transition from the high PNA binding, low tumorigenic phenotype of D2.OR cells
to the low PNA binding, highly tumorigenic phenotype of cells isolated from tumours resulting from s.c.
implantation of D2.OR cells. Taken together, these data illustrate that both quantitative and qualitative
changes in PNA binding glycoproteins occur sequentially during malignant transformation and progression of
murine mammary neoplasia. Stepwise simplification of the pattern of expression as well as selective sialylation
of some species occurred. Because low PNA-binding tumour cells develop after injection of the cloned, high
PNA-binding D2.OR, progression may occur on a cellular level rather than due to selection of a pre-existing
low PNA-binding subpopulation in the D2HAN-tumour system.
Alterations in cell surface carbohydrate expression during
neoplastic development have been frequently observed in man
and animals (Feizi, 1985a; Feizi, 1985b; Hakomori, 1989;
Smets & Van Beek, 1984; Yogeeswaran, 1983). This seems to
hold true for mammary neoplasia (Franklin, 1983; Gooi et
al., 1985a; Gooi et al., 1985b; Howard et al., 1981; McKenzie
& Xing, 1990; Muller-Holzner et al., 1985; Taylor-Papa-
dimitriou et al., 1990). The role of transformation events,
such as carcinogen treatment (Russo et al., 1988) or onco-
gene activation (Bolsher et al., 1988; Rak et al., 1991), in cell
surface carbohydrate alterations have been proposed. Despite
the wealth of information on tumour associated carbohyd-
rate structures it is unclear whether multiple sequential
genetic and phenotypic alterations driving tumour progres-
sion (Chen et al., 1989 and references therein) are paralleled
by a particular sequence of changes in cell glycosylation
patterns. On the other hand, the expression of certain carbo-
hydrates seems to be associated with differentiation of cell
components of the normal mammary gland (Rudland, 1987;
Rudland et al., 1989). In particular, differential binding of
Peanut agglutinin (PNA) to mammary cell subsets such as
alveolar, ductal, myoepithelial, and stromal cells was report-
ed in both human and rat systems (Rudland, 1987; Newman
et al., 1979). In our experience, also, murine epithelium but
not stroma is rich in PNA binding sites. We wished to
determine whether PNA binding characteristics are a func-
tion of mammary tumour progression for two reasons. First-
ly, knowing that high PNA binding is a differentiation
marker of some, but not all cells in the mammary gland we
were curious whether this feature is lost or amplified during
development of the neoplasia. In any case this could be a
result of eithuer clonal expansion of cells expressing a partic-
ular 'normal' PNA binding phenotype or expression of an
'abnormal' phenotype at the cellular level. Secondly, we were
interested in the possible relationship between the expression
of PNA reactive glycoconjugates and growth rate, tumori-
genicity, metastatic potential and other biological characteris-
tics of transformed mammary cells. Instead of examining
paired normal vs malignant or metastatic vs non-metastatic
cell types, we decided to analyse the full spectrum of progres-
sion from normal mammary epithelium to benign hyperplasia
to neoplasia including resulting tumour cell heterogeneity. In
this study we compared murine mammary cells at different
stages of progression with respect to PNA binding intensity
to the cell surface using flow cytometry and analysed expres-
sion of PNA reactive glycoproteins by SDS-PAGE.
Materials and methods
Tumours
The preneoplastic mammary hyperplastic alveolar nodule line
D2HAN (Medina, 1973) was the source of several tumours
(i.e., D2 tumours). EMT6R08 is a long established tumour
line derived from a D2 tumour (Loeffler et al., 1990; Rock-
well et al., 1972), and D2A1 and D2F2 are clones of a single
Correspondence: F.R. Miller.
Received 10 July 1991; and in revised form 19 November 1991.
Br. J. Cancer (I992), 65, 641 648 '." Macmillan Press Ltd., 1992642 J.W. RAK et al.
spontaneous D2 tumour (Mahoney et al., 1985). Polyclonal
cell populations derived from new spontaneous D2 tumours
arising from D2HAN-filled mammary fatpads were establish-
ed and maintained as primary or low passage cultures
(D2ST1, D2ST2, D2ST3, D2ST4 and D2ST5). Each spontan-
eous D2 tumour arose in a separate animal except D2ST2
and D2ST3 which came from one animal bearing two tumours
in D2HAN implanted fatpads on contralateral sides. D2.OR
is one of several clones derived from D2ST5. It was selected
for further studies because of its high PNA binding capacity.
The D2.OR clone was injected s.c. and, although it was
poorly tumorigenic, one of the few resulting tumours was
re-established in culture and cloned; D2.1 is one of those
randomly chosen clones. The in vivo passage of D2.OR cells
was performed in two more independent experiments each
time yielding a low PNA binding population (clonal or poly-
clonal) which in one of those experiments was retested for
tumorigenicity in syngeneic mice and was found similar to
highly tumorigenic D2.1 clone.
A series of sister cell populations derived from a single
spontaneous BALB/cfC3H mouse mammary tumour (Dexter
et al., 1978; Miller et al., 1986), lines 66c14, 67, 68H, 4T07,
44FTO, and 168FARN, express different phenotypes with
respect to in vivo and in vitro growth and metastasis. Line
64PT is a hybrid of 4TO7 and 68H (Miller et al., 1988b).
SPI(MIMl) is a metastatic variant of the SPI spontaneous
CBA/J mammary adenocarcinoma (Elliott et al., 1988)
obtained from Dr Bruce Elliott, Queens University, King-
ston, Ontario.
Tumour cells were grown in DME supplemented with 5%
fetal bovine serum (FBS), 5% calf serum (CS), 2 mM gluta-
mine, 100 U ml-' penicillin, 100jigml-' streptomycin and
1 mM of mixed nonessential amino acids. Culturing of
tumour cells in media used for mammary epithelium and
D2HAN (see below) did not alter any of their properties.
Primary cell culture
Tumours were dissociated mechanically and by treatment
with Collagenase type 3 (Worthington) 2 mgml-' and Hyal-
uronidase (Sigma) 1 mgml-' for 1 h on ice with subsequent
repetitive agitation for 30 s in a Stomacher Blender (Miller et
al., 1990). Normal mammary cell cultures were prepared
using the procedure described elsewhere (Miller & McIner-
ney, 1988). Briefly, mammary glands ofmidpregnant BALB/c
mice were aseptically removed, minced, and digested with an
enzyme cocktail containing Collagenase type III and hyal-
uronidase. The digest was then separated by double sedimen-
tation in Hank's Balanced Salt Solution (HBSS) followed by
20g centrifugation on FBS cushion for 1 min. The aggregates
(containing mostly epithelial cells) and single cells (mostly
stromal cells) were depleted of macrophages by adhesion to
plastic for 1 h at 37°C and then plated for 7-10 days in
medium. In some experiments stromal and epithelial cells
were plated unseparated. Cells were maintained in DME-10
containing 10% NCTC 109 medium (M.A. Bioproducts,
Walkersville, MD), 20 mM glucose, 8jigml-' bovine crystal-
lin insulin, and 1 mM oxaloacetic acid. Single cell suspensions
were prepared by conventional, brief treatment with 0.25%
trypsin in 0.05% EDTA.
Cell injection
Animals were injected with 0.2 ml of a single cell suspension
in HBSS (calcium and magnesium free). Subcutaneous (s.c.)
tumour growth was monitored by periodic measurements of
the length (a) and width (b) of tumour and subsequent
calculation of tumour weight according to the formula:
weight = a x b2/2. Tumour weight doubling time was esti-
mated by computerised exponential regression and calcula-
tion according to the formula: doubling time = ln2/k
(k-growth constant) (Rak et al., 1988). The number of lung
colonies which developed after intravenous (i.v.) cell injection
was determined at necropsy by counting the foci visible
under a dissecting microscope on the surface of Bouin
fixative-treated lungs.
In vitro growth rates were determined by plating 1 x 106
cells into 60mm tissue culture dishes and periodically har-
vesting and counting cells from three randomly chosen
dishes. Population doubling times were calculated by regres-
sion analysis.
Flow cytometry
The procedulre was described previously (Rak et al., 1991).
Briefly, cells were harvested with trypsin-EDTA solution,
incubated in DME-IOFBS for 1 h on ice, washed, pelleted,
and incubated for 40 min with 10-50,lg ml1' (usually 25;tg
ml-') of fluorescent Peanut lectin (PNA-FITC), Soy bean
agglutinin (SBA), or Griffonia simplicifolia isolectin (GSIB4)
in the presence (control) or absence ofan appropriate blocking
sugar (galactose, N-Acetylo- galactosamine, or alpha-methyl
galactopyranoside, respectively). All the lectin blocking
sugars were purchased from Sigma Chemical Co. (St Louis,
MO). In some experiments, prior to incubation with lectins,
cells were treated with 0.1 U ml-' neuraminidase (type V, Cl.
perfringens, Sigma Chemical Co., St Louis, MO). After
several washes, cells were fixed in 0.1% paraformaldehyde
and analysed by FACStar flow cytometer under 420 nm of
Innova 90 Argon laser light (Becton Dickinson, Mountain
View, CA). Mean specific fluorescence intensity was cal-
culated by subtraction of the mean fluorescence intensity of
cells incubated with sugar-inactivated lectin from the mean
fluorescence of cells stained with intact lectin. Significance of
differences was confirmed at the confidence level of P<0.001
according to Kolmogorow-Smirnow statistics. Some vari-
ability in modal fluorescence between different stainings of
the same cell population was seen. This was a result of
different batches and, in some cases, concentrations of the
fluorescent lectins used in individual experiments. Also set-
ting of the instrument for each individual analysis might have
been a source of some variability of the numerical values
describing fluorescence intensity. Parallel fluctuations of
those values were seen in control samples and between differ-
ent cell types, so they did not affect the results. We also
noticed that in the case of clonal D2 tumour cell lines
untreated with neuraminidase (D2.OR, D2.1, D2A1) the
staining intensity is up to 30% lower when the cells remain
confluent as compared to the cells in the log phase ofgrowth.
Although the cells were always analysed at approximately the
same (70-90%) confluency some fluorescence fluctuations
may be due to this phenomenon. The latter, however, did not
obscure several fold relative differences between the cell lines.
Also, size and direction of the confluency dependent shift was
similar for all of the three clonal D2 tumour cell lines. The
time course and nature of this confluence-related shift in
expression of PNA binding sites was not examined in detail.
Double staining with propidium iodide and PNA-FITC did
not suggest any S-phase specific expression of the lectin
binding sites for any of these lines.
PNA overlays
Semiconfluent cell cultures were harvested with 2 mM EDTA,
washed in PBS, pelleted, and treated with lysis buffer con-
taining 0.5% NP-40, 1 mM EDTA, and 1 mM phenylmethyl-
sulfonylfluoride in PBS. The protein equivalent of 3 x 106
cells was separated by SDS-PAGE in 8% gel under reducing
conditions, transferred to a nitrocellulose filter, and treated
(or not) with 1 mUml1' neuraminidase type V and with
0.25 ugml-' of PNA. The lectin binding protein was visual-
ised by autoradiography after incubating the filter with anti-
PNA rabbit antibody (Accurate Chemicals and Scientific
Corporation, Westbury, NY) followed by incubation in anti-
rabbit I'25-labelled antibody (Amersham).
Results
The cultured cells from normal mammary gland stained
strongly and specifically with PNA-FITC (Figure 1). Popula-ALTERED PNA BINDING DURING PROGRESSION 643
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respectively high and low PNA binding (Figure 2). Staining
with Soybean agglutinin (SBA) or Griffonia simplicifolia iso-
lectin (GSIB4) did not reveal any difference between epithe-
lial and stromal mammary components (not shown).
A gradual decrease in PNA binding (Figure 3a and 3b) but
not in SBA binding (Figure 3c) accompanied progression
from preneoplastic D2HAN lesions to spontaneous D2HAN
derived tumours and highly malignant clonal cell lines D2A1
and D2F2. Histogram overlaps in Figure 3 suggest a great
deal of variability and perhaps the presence of high and low
PNA binding subpopulations within both preneoplastic
D2HAN lesions and tumours. By isolating and screening
several clones from a spontaneous D2 tumour, one clonal
nonulation (D2 0R) was ohtained which stained verv stronalv
WItLn riNt-ri1iL rigure '). rrom a tumour iormeu atter
injecting 1 x 106 D2.OR cells s.c., a primary tissue culture was
established. D2.1 is representative of eight clones obtained
from that culture. The ability of clone D2.1 to bind PNA
was intermediate to the parental D2.OR clone and the highly
malignant D2A1 tumour line (Figure 4). Having a panel of
those three clonal D2HAN derived tumour cell lines express- C
ing high, intermediate and low PNA binding ability, we began )
to compare their malignant properties. Clones D2A1 (low -) E
and D2.1 (intermediate PNA binding) were able to generate
100% incidence of s.c. tumours when as few as 5 x I04 cells
were injected, whereas D2.OR (high PNA binding) failed to u
initiate tumours in those experiments and initiated tumours
in less than 100% animals after injection of 5 x 105 cells (not
shown). The differential growth kinetics of these lines after
s.c. iniection of 1 x 106 cells is shown in Figure 5. All three
Log fluorescence intensity
Figure 3 PNA-FITC binding profiles of normal mammary cells
(MAM), preneoplastic (D2HAN tissue), tumour derived (D2HAN
tumour) and malignant D2HAN related clones (D2A1, D2F2) -
10° lo1 102 1o3 two experiments are shown in panels a and b. SBA-FITC staining
Log fluorescence intensity of normal mammary cells (MAM) and three D2HAN related
tumour cell populations -panel c.
Figure 1 PNA-FITC binding profiles of normal mammary cells
(MAM) stained with 50kg ml-' of intact (MAM-PNA) or 0.2 M
galactose inactivated (MAM-GAL) lectin.
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FL1 Figure 4 PNA-FITC binding profiles of three D2HAN derived
tumour cell clones: D2Al ( ), D2.1 (-.---), and D2.OR (----). Figure 2 PNA-FITC (25pgmlm') binding profiles of epithelial Staining of D2.OR was significantly greater (P<0.001) than
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Figure 5 Tumour growth of three D2HAN derived tumour cell
clones: D2A1 (0), D2.1 (@), D2.OR (U). For each tumour line
5-6 syngeneic BALB/c mice were injected s.c. with 1 x 106 cells.
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Figure 6 Lung colonisation potential of three D2HAN derived
tumour cell clones after i.v. injection of 5 x 105 cells.
lines produced tumours when 1 x 106 cells were injected s.c.
Line D2A1 had the shortest latency and a faster growth rate
(doubling time of 8 days) than either D2.1 or D2.0R. High
PNA binding line D2.OR had a longer latency than line D2.1
but the growth rate of the two was similar once palpable.
The ability to form lung colonies after i.v. injection of
5 x I05 was greatest for D2A1 cells (Figure 6). All the mice
developed visible nodules by the time of necropsy at 28 days.
The number of lung colonies per lung ranged between 11 and
38 (median 19). Furthermore, extrapulmonary foci in liver,
kidney, eye, and subcutis were found in 67% of animals.
After injection of D2.1 or D2.OR cells, single lung colonies
appeared in some mice by the time of necropsy (72 days). No
extrapulmonary deposits were found. Neither could we find
spontaneous metastases after s.c. injection of those two cell
lines; however, spontaneous metastases were observed in
mice bearing s.c. D2A1 tumours (not shown). Despite differ-
ences described above, the three D2HAN derived tumour cell
population had similar in vitro growth potential. Doubling
time of D2AI line (0.68 ± 0.15 days) was slightly shorter
than that for D2.1 or D2.OR cells (0.76 ± 0.10 and 0.75 +
0.10 days, respectively).
To determine the kinetics of the loss of PNA-binding
capacity, tumours were initiated by s.c. injection of 1 x 106
D2.OR cells. The two largest of the early appearing tumours
were removed after 67 days of growth (tumour weights 108
and 600 mg) and cells cultured. Later, on day 103, two large
(5235 mg and 3179 mg) and two smaller tumours (847 mg
and 196 mg) were used to establish primary tissue cultures.
After 3-4 passages in vitro the PNA binding abilities of these
cell populations were compared to the parental D2.OR clone
(Figure 7). The lectin reactivity ofcells derived from the large
tumours was substantially (four times) lower than that of the
parental line (P<0.001). Cells derived from large tumours
were also more tumorigenic after injection of I x 106 cells s.c.
than parental D2.OR cells (not shown). Small and early
tumour-derived cells displayed intermediate values suggesting
that the process oflosing the expression ofPNA binding sites
is gradual and time dependent. Only in vivo passage was able
to cause that effect since the D2.OR clone maintained its
PNA-binding phenotype for several months in culture (not
shown).
Differential sialylation of the lectin binding sites apparently
plays a role in these phenotypic changes because neura-
minidase treatment was able to abrogate the quantitative
differences (not shown). Qualitative analysis of the pattern of
PNA binding glycoproteins (Figure 8) revealed the presence
of a highly PNA-reactive high molecular weight band
(approximately 150 Kd) in lysates of parental clone D2.OR
cells which is missing in lysates of the tumour derived cells
including clone D2.1 obtained from D2.OR tumour. Desialyl-
ation of that material revealed virtually identical patterns
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Figure 7 PNA-FITC binding to clone D2.OR, its subclone D2.1,
and uncloned populations derived from tumours formed after
injecting I x 106 D2.OR cells s.c. (early tumour, ET; small late
tumour, Sm; and large late tumour, Lg). Means represent three
experiments of D2.OR, D2.1, ET, and Lg, but Sm was analysed
only twice. Staining of D2.OR cells was significantly greater than
the staining of ET (P<0.05), Sm (P<0.01), Lg (P<0.01), or
D2.1 (P<0.001). Staining of ET was significantly greater than
Sm, Lg, or D2.1 (P<0.001).
2.0R ET ST LT 2o1
aa _ _
,:.: .. .... ..........::....................^-..-:.o::...:.;
. ..
..:..,.t.:-:^t-.....::...',:.
:: ::. ...
'i: ;......'...'..........-....:'''.......:<.::
5 -....:....'...:
. :: Pv-....:.....:...^::.s:^
2.OR ET ST LT 2.1
-200
-92.5-
-69
-46-
-...30-3o
No neuraminidase After neuraminidase
treatment
Figure 8 PNA reactive glycoproteins in whole cell lysates of
clone D2.OR, subclone D2.1, and uncloned populations derived
from tumours formed by injecting D2.OR cells s.c.
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consisting of four PNA reactive common bands (220 kd,
180 kd, 150 kd and 85 kd) for both parental D2.OR cells and
tumour derived cells. This suggests that specific sialylation of
gp 150 contributes to the differences observed.
Several established mammary tumour cell lines displayed
rather weak PNA binding capacities (Table I). Although
some variability among them was found, no general correla-
tion between PNA staining intensity and expression of
known biological characteristics such as growth and metas-
tatic potentials or drug resistance was found. With the excep-
tion of the poorly tumorigenic clone D2.0R, cells from D2
series of premalignant HAN lesions bound less PNA-FITC
than cells from normal mammary gland and from D2HAN
preneoplastic lesions (Figure 4, Table I). This includes both
established cell lines (D2A1, D2F2, EMT6RO8) and primary
cultures of D2HAN derived tumours (Table I). Because pre-
treatment with neuraminidase abolishes the differential bind-
ing of PNA by normal and transformed mammary cells
(Table I), differential sialylation rather than an absolute
absence of PNA-specific oligosaccharides on the cell surface
may be responsible. In many cases, however, the expression
of tumorigenic potential seems to be associated with low
PNA binding to mammary cells.
A single PNA reactive band (220 kd) common for normal,
premalignant, and malignant mammary cells was observed
(Figure 9). Regardless of neuraminidase treatment, lysates of
D2HAN derived tumours and BALB/cfC3H tumours did not
exhibit the very large molecular weight band (>250 kd) seen
in D2HAN and normal mammary epithelium (arrow, Figure
9). A major band of approximately 90 kd was present in
lysates of normal mammary epithelium, but not in D2HAN
or any tumour cell types. A band of this size was present in
some tumour cell lysates following neuraminidase treatment.
A major band of approximately 150 kd was detected in
lysates of normal mammary epithelium and to a lesser extent
in preneoplastic D2HAN cells. This band was detected in
poorly tumorigenic D2.0R cells and almost completely disap-
peared from the material obtained from D2Al malignant
cells. This band was detected in other tumour lysates after
neuraminidase treatment.
Discussion
We were struck by the observation that PNA binding to
neoplastic mammary cells was dramatically reduced in com-
parison to their normal epithelial counterparts. Neura-
minidase treatment resulted in abrogation of that difference
indicating that masking of the lectin binding sites by sialic
acid was involved. A similar difference was observed in three
unrelated panels of mammary tumour cell populations deriv-
ed from spontaneous tumours which arose in three different
strains of syngeneic mice.
It is well documented that abnormal expression of carbo-
hydrates correlates with neoplasia (Feizi, 1985a); Hakomori,
1989). Roles for both N-linked (Dennis & Laferte, 1989 and
references therein) and 0-linked (Schirrmacher, 1982) oligosac-
charides in invasion and metastasis have been postulated.
Oncodevelopmental antigens have been detected in breast
cancer specimens using monoclonal antibodies specific for
blood group related carbohydrates (Feizi, 1985a; Feizi,
1985b; Gooi, 1985a; Gooi, 1985b) and PNA (Springer, 1984).
Sialylation of various glycoconjugates correlates with metas-
tatic phenotype in different systems (Benedetto et al., 1989;
Bresalier et al., 1990; Corfield et al., 1990; Friedman et al.,
1988; Passaniti & Hart, 1988; Dennis et al., 1989). However,
there is also evidence indicating that in some systems the
expression of non-sialylated structures binding SBA (Buckey
et al., 1988) or PNA (Badenoch-Jones et al., 1987; Schirr-
macher et al., 1982) is associated with metastasis. Sialylation
of surface carbohydrates was alternatively correlated with cell
proliferation (Kinoshita et al., 1989) or differentiation (Kino-
shita et al., 1989; Kuratsu et al., 1990). In some reports only
subtle changes in glyconjugate expression patterns were seen
Table I Flow cytometry analysis of PNA-FITC binding to mouse mammary tumour
cells
Mean relativefluorescence intensity
(% normal) Characteristics
Tumour cell Neuraminidase
population (-)Neuraminidase treated TUM LCF MET
Clonal cell lines established from mammary tumours derived from D2HAN lesions
D2.OR 183,388 133,183 +/- - -
D2.1 36,44,51,53,53,67 148 +
D2A1 4,7,9,12,23 74,80,124 + + + +++ +
D2F2 8 87 + + + ND ND
EMT6RO8 14 ND + + ND ND
Polyclonal cell populations isolated from D2HAN derived mammary tumours
(passage #1-5)
D2ST1 25,36 156 NT NT
D2ST2 45 172 NT NT
D2ST3 22 138 NT NT
D2ST4 29 ND NT NT NT
Clonal subpopulations derived from a single spontaneous mammary tumour in
BALB/cfC3H mouse
67 1,2 ND ++ - -
66c14 2,2 57 +++ +++ +++
168FARN 19 114 +++ +++ -
4T07 1,2 91 +++ ++++ +/-
68H 4 85 +/- ND ND
64pT 3,7,12 99 ++ ++ +
Subpopulation of the spontaneous mammary carcinoma in CBA/J mouse
SPI(MlMI) 30 ND +++ ND ND
Mean specific fluorescence intensity was calculated by subtraction of the mean
fluorescence intensity ofcells incubated with galactose-inactivated lectin from the mean
fluorescence ofcells stained with intact lectin. Mean relative fluorescence intensity is the
percent of the mean specific fluorescence intensity of mouse mammary epithelial cells.
Each value represents an individual experiment. TUM - tumorigenicity after s.c.
inoculation; LCF - lung colony formation after i.v. injection of tumour cells; MET -
spontaneous metastasis in distant organsdetected atautopsy oftheprimary orsecondary
tumour bearer; ND - not done; NT - no transplantation to a secondary bearer was
performed.646 J.W. RAK et al.
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Figure 9 PNA reactivity of SDS-PAGE separated glycoproteins
from whole cell lysates isolated from neoplastic (lanes 1-7),
preneoplastic (lane 8), and normal (lane 9) mammary cell popula-
tions with or without neuraminidase treatment.
between more and less malignant cell lines (Steck & Nicol-
son, 1983; Tresser & Nicholson, 1988). Some studies suggest
that sugar structures are directly involved in determination of
cell phenotype due to modification of physical and/or bio-
chemical properties of their surfaces (Dennis & Laferte, 1989;
Friedman et al., 1988; Schirrmacher et al., 1982). The impor-
tance of a particular structure seems to depend on the genetic
background of cells expressing it. For example PNA receptor
is normally expressed by human gastric mucosa of so called
'non-secretors' but is considered to be a tumour associated
feature in 'secretors' (Feizi, 1985b). Species specificity was
also reported (Galili & Machmer, 1989). On the other hand
specific functions of some adhesion molecules, their ligands
and other important known glycoconjugates were shown to
be regulated by their glycosylation (Diamond et al., 1991;
Larsen et al., 1990; Oz et al., 1989; Rabinovitz et al., 1991).
Depite the plethora of information, which was only
exemplified above, the clue for understanding the role of
aberrant glycosylation in tumour progression seems still to be
missing. The most common strategy in this area of research
has been an analysis of paired cell populations usually
representing a rather narrow 'window' of the whole process,
for example a transition from low to high metastatic
phenotype. We felt that because of the stepwise nature of
tumour progression at the genetic level (Chen et al., 1989 and
references therein) glycosylation changes may also follow a
sequential course. This implies that initial conditions
(differentiated phenotype) might be important. The expres-
sion of differentiation related carbohydrates recognisable by
lectins was reported for several systems including
hematopoietic cells (Reimann et al., 1984), endothelium
(Alroy et al., 1987) and mammary epithelium (Rudland,
1987). The latter comprises several phenotypically distinct
cell populations (Rudland, 1987; Sonnenberg et al., 1986).
Interestingly, in rat and humans the main populations can be
classified on the basis of their PNA binding patterns (Rud-
land, 1987; Newman et al., 1979). In these studies ductal and
alveolar cells bound the lectin with or without neuraminidase
treatment, respectively. Myoepithelial and stromal cells were
negative regardless of neuraminidase treatment. In the
murine system we observed PNA binding sites widely dist-
ributed amongst mammary cell populations in culture (see
Figure 1). Flow cytometry, however, clearly showed 20-fold
lower PNA binding to stromal cells than to mammary
epithelium (compare Figure 2) thus indicating the quan-
titative nature of this differentiation marker. Further analysis
revealed sequential quantitative and qualitative changes in
PNA binding pattern during development of preneoplastic
hyperplastic (D2HAN) and subsequent progression of the
neoplasia. (i) We observed a gradual decrease in expression
of PNA binding sites throughout the whole process. No such
general trend was seen in binding of SBA, GSIB4, or L-PHA
(Rak, Miller, unpublished). (ii) We observed an inverse cor-
relation of PNA binding capacity and the expression of the
malignant phenotype (tumorigenicity, metastatic potential)
among D2HAN related cells seen in flow cytometry and
preliminary clonal analysis suggest that most of the PNA
binding sites are being lost during transition from the
premalignant to tumorigenic state probably due to progres-
sive cellular alterations rather than selection of pre-existing
populations within D2HAN lesion (compared phenotypes of
related clones D2.0R and D2.1). There are metastatic and
nonmetastatic populations amongst the low PNA binding
tumour cell lines derived from BALB/cfC3H mouse mam-
mary tumour (see Table I) but we have not observed a
metastatic and at the same time highly PNA binding mam-
mary tumour. (iii) There was a loss of high molecular weight
(conceivably mucin-like) PNA reactive glycoproteins
(>250kd) during transition from hyperplasia to neoplasia;
(iv) loss or hypersialylation of 90kd glycoprotein during
development of neoplasia; and (v) hypersialylation of 150 kd
glycoprotein in the case of highly tumorigenic but not in
normal, preneoplastic and poorly tumorigenic D2.OR mam-
mary cells. Recognition of these alterations leads to several
further questions. First, do they represent consequences
(markers) of tumour progression or are some of them neces-
sary components of the malignant phenotype. Second, which
component of a particular change is essential; the carbohyd-
rate structure or the whole glycoprotein? Structural analysis
of carbohydrates recognised by PNA (T-antigen and other
terminal galactose-rich 0-linked structures) can be analysed
by using a panel of monoclonal antibodies (Feizi, 1985;
Hakomori, 1989). We also intend to screen our material with
antibodies recognising known molecules of corresponding
size potentially involved in tumour progression. Mammary
mucins (Taylor-Papadimitriou et al., 1990; McKenzie et al.,
1990), E-cadherins (Nagafuchi et al., 1987), CD44 (Brown et
al., 1991) or betal integrin (Oz et al., 1989) are some of the
obvious candidates. There is also an interesting size similarity
between a sialylated gp 150 involved in liver metastasis for-
mation by murine leukaemia cells (Benedetto et al., 1989)
and the 150 kd glycoprotein sialylated during in vivo passage
of mammary D2.OR tumour cells. Sialylation of the latter
molecule appeared to be involved in full expression (or
derepression?) of tumorigenicity. Interestingly, the highly
tumorigeneic subclone (D2.1) and polyclonal populations
(ET, Lg, Sm), all expressing the sialylated form of thisALTERED PNA BINDING DURING PROGRESSION 647
glycoprotein (see Figure 7), seem to be generated during
interaction of the parental D2.OR clone with host environ-
ment since hypersialylation of that molecule occurred only
after in vivo passage, but not during several months in cul-
ture. It is premature to speculate on mechanisms of this
phenotypic switch in vivo until they can be reproduced by
relevant in vitro systems. Both selection against high PNA
binding variants and induction of the low PNA binding
phenotype are conceivable. We are currently exploring a
number of possibilities including tumour cell interaction with
stromal cells, with extracellular matrix, and with the immune
system.
Thus, we have been able to demonstrate a series of sequen-
tial quantitative and qualitative changes in expression of
PNA reactive glycoconjugates during murine mammary
tumour development and progression. Further studies on the
nature of those alterations and identity of molecules involved
are currently being pursued. Hypersialylation of a 150kd
glycoprotein seems to be important for host-dependent
modulation of the tumorigenic phenotype of transformed
mammary cells.
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